Skip to content

CYTOSORBENTS CORPORATION: 10-Q filed 2024-08-13

What CYTOSORBENTS CORPORATION reported in its quarterly report filed 2024-08-13 (fiscal Q2 2024): 42 published measures, 119 facts as tagged in accession 0001410578-24-001368.

This filing

Form
10-Q (quarterly report)
Filed
2024-08-13
Fiscal period
fiscal Q2 2024
Accession
0001410578-24-001368 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CYTOSORBENTS CORPORATION filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-06-3053,426,791USD
At 2023-12-3153,260,634USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-06-3036,690,188USD
At 2023-12-3129,985,471USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-06-3016,736,603USD
At 2024-03-3118,927,925USD
At 2023-12-3123,275,163USD
At 2023-06-3024,094,696USD
At 2023-03-3128,955,445USD
At 2022-12-3135,374,973USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-06-308,458,708USD
At 2023-12-3114,131,137USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-4,143,146USD91
2024-01-01 to 2024-06-30-10,501,007USD182
2023-04-01 to 2023-06-30-6,153,084USD91
2023-01-01 to 2023-06-30-13,478,967USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-06-30-9,624,412USD182
2023-01-01 to 2023-06-30-10,041,497USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-06-309,262,875USD182
2023-01-01 to 2023-06-301,615,401USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-01-01 to 2024-06-30-246,883USD182
2023-01-01 to 2023-06-30-542,599USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-06-30-293,006,279USD
At 2023-12-31-282,505,272USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-04-01 to 2024-06-3054,306,041shares91
2024-01-01 to 2024-06-3054,284,416shares182
2023-04-01 to 2023-06-3044,015,380shares91
2023-01-01 to 2023-06-3043,758,888shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-04-01 to 2024-06-3054,306,041shares91
2024-01-01 to 2024-06-3054,284,416shares182
2023-04-01 to 2023-06-3044,015,380shares91
2023-01-01 to 2023-06-3043,758,888shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-0.08USD/shares91
2024-01-01 to 2024-06-30-0.19USD/shares182
2023-04-01 to 2023-06-30-0.14USD/shares91
2023-01-01 to 2023-06-30-0.31USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-0.08USD/shares91
2024-01-01 to 2024-06-30-0.19USD/shares182
2023-04-01 to 2023-06-30-0.14USD/shares91
2023-01-01 to 2023-06-30-0.31USD/shares181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-06-309,423,649USD
At 2023-12-3110,056,354USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-01-01 to 2024-06-301,562,792USD182
2023-01-01 to 2023-06-301,400,516USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-3,418,822USD91
2024-01-01 to 2024-06-30-8,344,341USD182
2023-04-01 to 2023-06-30-6,559,237USD91
2023-01-01 to 2023-06-30-14,450,832USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-06-3021,955,300USD
At 2023-12-3125,702,823USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-06-3010,336,268USD
At 2023-12-3114,545,955USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-06-303,047,038USD
At 2023-12-313,802,170USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2024-06-307,822,823USD
At 2023-12-316,057,072USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-04-01 to 2024-06-309,921,551USD91
2024-01-01 to 2024-06-3021,417,648USD182
2023-04-01 to 2023-06-3012,577,787USD91
2023-01-01 to 2023-06-3025,924,709USD181

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2024-06-304,316,752USD
At 2023-12-313,680,129USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2024-04-01 to 2024-06-306,502,729USD91
2024-01-01 to 2024-06-3013,073,307USD182
2023-04-01 to 2023-06-306,018,550USD91
2023-01-01 to 2023-06-3011,473,877USD181

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2024-04-01 to 2024-06-307,581,201USD91
2024-01-01 to 2024-06-3016,148,400USD182
2023-04-01 to 2023-06-307,723,952USD91
2023-01-01 to 2023-06-3016,187,226USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-04-01 to 2024-06-301,519,618USD91
2024-01-01 to 2024-06-303,767,811USD182
2023-04-01 to 2023-06-303,668,804USD91
2023-01-01 to 2023-06-307,883,219USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-06-3054,306,415shares
At 2023-12-3154,240,265shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-06-3014,942,666USD
At 2023-12-3115,615,095USD
At 2023-06-3014,838,983USD
At 2022-12-3123,832,026USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-06-30307,514,758USD
At 2023-12-31305,196,874USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2024-06-302,173,818USD
At 2023-12-31529,321USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2024-06-3011,789,539USD
At 2023-12-3112,058,896USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2024-06-3013,092,792USD
At 2023-12-3113,270,295USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2024-06-3013,673,195USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-06-303,774,345USD
At 2023-12-313,958,603USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2024-06-301,357,017USD
At 2023-12-311,834,485USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-4,143,146USD91
2024-01-01 to 2024-06-30-10,501,007USD182
2023-04-01 to 2023-06-30-6,153,084USD91
2023-01-01 to 2023-06-30-13,478,967USD181

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-3,721,824USD91
2024-01-01 to 2024-06-30-8,856,510USD182
2023-04-01 to 2023-06-30-6,545,758USD91
2023-01-01 to 2023-06-30-14,479,849USD181

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-4,143,146USD91
2024-01-01 to 2024-06-30-10,501,007USD182
2023-04-01 to 2023-06-30-6,153,084USD91
2023-01-01 to 2023-06-30-13,478,967USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-724,324USD91
2024-01-01 to 2024-06-30-2,156,666USD182
2023-04-01 to 2023-06-30406,153USD91
2023-01-01 to 2023-06-30971,865USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2024-01-01 to 2024-06-30537,672USD182
2023-01-01 to 2023-06-30173,334USD181

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2024-04-01 to 2024-06-30566,000USD91
2024-01-01 to 2024-06-301,137,000USD182
2023-04-01 to 2023-06-30466,000USD91
2023-01-01 to 2023-06-301,099,000USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-06-301,952,413USD182
2023-01-01 to 2023-06-301,271,716USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-06-30725,998USD182
2023-01-01 to 2023-06-30-1,449,881USD181

Inspect the source

Entity
CYTOSORBENTS CORPORATION / CIK 0001175151
Captured
2026-09-20T07:44:44.168Z
SEC response SHA-256
8bb195ec858f16302b2a8454a5ffe3eff6c1e6cd0312136a64a7a2f621b86836

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001175151.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))